$GH

Tariq Musa sold $15K of GH

Tariq Musa sold 116 shares of Guardant Health, Inc. (GH) at $130.19 on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tariq Musa
Published Jun 16, 2026, 8:37 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

This is a disclosed director open-market sale under a pre-arranged Rule 10b5-1 plan; absent other new company information, it is typically treated as low-signal for fundamentals.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

The article doesn’t state whether other insiders are buying/selling, nor the broader context of Musa’s total holdings beyond the post-transaction figure.

Relevance 2/10Novelty 6/10Timing: Filed 2026-06-16 (transaction dated 2026-06-16)

Background

The article is an SEC Form 4 insider transaction disclosure for Guardant Health, reported via EDGAR.

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Guardant Health director Tariq Musa filed an SEC Form 4 selling 116 shares at $130.19 on 2026-06-16 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any reaction should be small and quickly mean-reverting.

Evidence & confidence

The filing is a small, pre-arranged 10b5-1 open-market sale by a director, with no accompanying operational/regulatory/financial catalyst in the text.

Market effects

No sector-level read-through; this is company-specific insider liquidity disclosure only.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with periods of valuation/positioning changes; traders may still watch for follow-on insider buys or larger transactions.

Key entities

  • Guardant Health, Inc.

    Company whose director insider transaction was disclosed on SEC Form 4.

  • Tariq Musa

    Director who sold 116 shares on 2026-06-16 under a 10b5-1 plan.

Related articles

$GHHighAI 9/10

Guardant Health (GH) Q2 2026 Earnings Call Transcript

Guardant Health (GH) reported Q2 2026 revenue of $335 million, up 44% year over year, driven by Oncology, Biopharma & Data, and Screening. Oncology revenue was $219.1 million, up 38%, with test volumes around 104,000. Full-year guidance: revenue $1.34 to $1.36 billion and free cash flow burn $195 to $205 million.

$GHMedAI 8/10

New blood test to detect colon cancer clears FDA approval

The FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in adults aged 45+ at average risk. In a study of 48,000+ people, it detected about 80% of colorectal cancers and correctly tested negative in about 90% without cancer or advanced precancer. It is expected to launch this fall with Abbott. Guardant Health’s Shield was approved in 2024.

$GHMedAI 8/10

Guardant Health, Inc. Q2 2026 Earnings Call Summary

Guardant Health reported 44% YoY Q2 2026 revenue growth, citing strong Oncology and Screening performance. It raised full-year 2026 revenue guidance to $1.34B-$1.36B and expects lower Shield cost per test. FDA approval of Guardant360 Liquid CDx and UnitedHealth coverage for Shield from Aug. 1, 2026 are key catalysts.

$GHHighAI 9/10

Why is Guardant Health stock surging today?

Nasdaq sees best day in over a month as Microsoft breathes life back into AI trade Investing.com -- Guardant Health stock surged 8.8% in after-hours trading after the Palo Alto-based liquid biopsy pioneer reported second-quarter 2026 results that significantly exceeded revenue expectations, with sales reaching $335 million — a 44% year-over-year increase that beat the Wall Street consensus of roughly $314 million by approximately 6.4%.